Skip to main content
placeholder image

Preventing and treating olanzapine-induced obesity with betahistine: a chronic animal model study

Conference Paper


Abstract


  • Objective : Olanzapine, an atypical antipsychotic drug, is widely

    prescribed to treat schizophrenia, but induces serious weight gain/

    obesity side-effects. Antipsychotic drugs antagonistic affinity for histamine

    H1 receptors is the main indicator of weight gain side-effects.

    This study aimed to investigate whether chronic treatment with

    betahistine (H1 receptor agonist/H3 receptor antagonist) could prevent/

    treat olanzapine-induced weight gain at different stages of

    treatment.

    Methods : Female Sprague-Dawley rats were administered under 5

    conditions (n=12) : (1) Rats were treated with vehicle (control) during

    whole experimental period ; (2) ‘‘Obesity treatment group’’ : 5 weeks

    olanzapine treatment (1 mg/kg, t.i.d.), followed by 6 weeks coadministration

    of olanzapine with betahistine (9.6 mg/kg, t.i.d.) ;

    (3) ‘‘Obesity prevention group’’ : 3.5 weeks olanzapine treatment,

    followed by 2.5 weeks withdrawed, then co-administration of olanzapine

    and betahistine (4.8 mg/kg, t.i.d.) was introduced ; (4) Sole

    olanzapine treatment following the same time course as Group 3 ;

    (5) Rats were treated solely with betahistine (4.8 mg/kg, t.i.d.) during

    weeks 7–11.

    Results : Compared to controls, olanzapine treatment increased

    body weight (p<0.001), food intake (p<0.01), inguinal fat mass

    (p<0.05) and liver weight (p<0.01). On the other hand, the ‘‘obesity

    treatment group’’ had lower weight gain (p<0.001), food intake and

    inguinal fat (p<0.05) than the sole olanzapine treatment group.

    The ‘‘Obesity prevention group’’ also showed significantly decreased

    weight gain (p<0.05), compared to the olanzapine group.

    Conclusion: This study revealed that chronic co-treatment of

    olanzapine and betahistine is effective at reducing olanzapineinduced

    obesity side-effects. These results provide support for further

    clinical trials to improve of olanzapine-induced obesity side-effects

    using betahistine co-treatment.

Publication Date


  • 2012

Citation


  • Lian, J., Huang, X., Pai, N. B. & Deng, C. (2012). Preventing and treating olanzapine-induced obesity with betahistine: a chronic animal model study. The International Journal of Neuropsychopharmacology: Abstracts from the 28th CINP World Congress of Neuropsychopharmacology (pp. 56-56). United Kingdom: Cambridge Journals.

Ro Metadata Url


  • http://ro.uow.edu.au/medpapers/563

Start Page


  • 56

End Page


  • 56

Place Of Publication


  • United Kingdom

Abstract


  • Objective : Olanzapine, an atypical antipsychotic drug, is widely

    prescribed to treat schizophrenia, but induces serious weight gain/

    obesity side-effects. Antipsychotic drugs antagonistic affinity for histamine

    H1 receptors is the main indicator of weight gain side-effects.

    This study aimed to investigate whether chronic treatment with

    betahistine (H1 receptor agonist/H3 receptor antagonist) could prevent/

    treat olanzapine-induced weight gain at different stages of

    treatment.

    Methods : Female Sprague-Dawley rats were administered under 5

    conditions (n=12) : (1) Rats were treated with vehicle (control) during

    whole experimental period ; (2) ‘‘Obesity treatment group’’ : 5 weeks

    olanzapine treatment (1 mg/kg, t.i.d.), followed by 6 weeks coadministration

    of olanzapine with betahistine (9.6 mg/kg, t.i.d.) ;

    (3) ‘‘Obesity prevention group’’ : 3.5 weeks olanzapine treatment,

    followed by 2.5 weeks withdrawed, then co-administration of olanzapine

    and betahistine (4.8 mg/kg, t.i.d.) was introduced ; (4) Sole

    olanzapine treatment following the same time course as Group 3 ;

    (5) Rats were treated solely with betahistine (4.8 mg/kg, t.i.d.) during

    weeks 7–11.

    Results : Compared to controls, olanzapine treatment increased

    body weight (p<0.001), food intake (p<0.01), inguinal fat mass

    (p<0.05) and liver weight (p<0.01). On the other hand, the ‘‘obesity

    treatment group’’ had lower weight gain (p<0.001), food intake and

    inguinal fat (p<0.05) than the sole olanzapine treatment group.

    The ‘‘Obesity prevention group’’ also showed significantly decreased

    weight gain (p<0.05), compared to the olanzapine group.

    Conclusion: This study revealed that chronic co-treatment of

    olanzapine and betahistine is effective at reducing olanzapineinduced

    obesity side-effects. These results provide support for further

    clinical trials to improve of olanzapine-induced obesity side-effects

    using betahistine co-treatment.

Publication Date


  • 2012

Citation


  • Lian, J., Huang, X., Pai, N. B. & Deng, C. (2012). Preventing and treating olanzapine-induced obesity with betahistine: a chronic animal model study. The International Journal of Neuropsychopharmacology: Abstracts from the 28th CINP World Congress of Neuropsychopharmacology (pp. 56-56). United Kingdom: Cambridge Journals.

Ro Metadata Url


  • http://ro.uow.edu.au/medpapers/563

Start Page


  • 56

End Page


  • 56

Place Of Publication


  • United Kingdom